EDGAR·FLOW

Marker Therapeutics, Inc. — Form 10-Q

Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q — Neutral significance 8/100
What the filing says
Juan Vera, serving as President, CEO, Treasurer, and Principal Financial Officer, certified on November 16, 2026 that Marker's Q3 2026 10-Q fairly presents financial condition and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud were disclosed. The filing contains only standard Sarbanes-Oxley certification exhibits (31.1, 31.2, 32.1, 32.2) with no substantive operational or financial announcements.
Why this rating

Routine quarterly certification exhibits; no business events, transactions, or disclosures described. Standard procedural compliance filing.

View original filing on SEC.gov ↗ MRKR · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.